MX2021000397A - Moleculas de union a mesotelina y cd137. - Google Patents
Moleculas de union a mesotelina y cd137.Info
- Publication number
- MX2021000397A MX2021000397A MX2021000397A MX2021000397A MX2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A MX 2021000397 A MX2021000397 A MX 2021000397A
- Authority
- MX
- Mexico
- Prior art keywords
- mesothelin
- binding molecules
- antibody molecules
- msln
- binding site
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811450.4A GB201811450D0 (en) | 2018-07-12 | 2018-07-12 | Mesothelin and CD137 binding molecules |
| PCT/EP2019/068817 WO2020011976A1 (en) | 2018-07-12 | 2019-07-12 | Mesothelin and cd137 binding molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000397A true MX2021000397A (es) | 2021-05-27 |
Family
ID=63273224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000397A MX2021000397A (es) | 2018-07-12 | 2019-07-12 | Moleculas de union a mesotelina y cd137. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US12319739B2 (enExample) |
| EP (1) | EP3820894B1 (enExample) |
| JP (2) | JP7360441B2 (enExample) |
| KR (1) | KR20210030925A (enExample) |
| CN (1) | CN112437776B (enExample) |
| AR (1) | AR115769A1 (enExample) |
| AU (1) | AU2019303081A1 (enExample) |
| BR (1) | BR112021000396A2 (enExample) |
| CA (1) | CA3103173A1 (enExample) |
| DK (1) | DK3820894T3 (enExample) |
| ES (1) | ES3035107T3 (enExample) |
| FI (1) | FI3820894T3 (enExample) |
| GB (1) | GB201811450D0 (enExample) |
| HR (1) | HRP20250872T1 (enExample) |
| HU (1) | HUE072217T2 (enExample) |
| IL (1) | IL280007B2 (enExample) |
| MX (1) | MX2021000397A (enExample) |
| PL (1) | PL3820894T3 (enExample) |
| PT (1) | PT3820894T (enExample) |
| SG (1) | SG11202011960XA (enExample) |
| TW (1) | TWI839365B (enExample) |
| WO (1) | WO2020011976A1 (enExample) |
| ZA (1) | ZA202007570B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018142573A (ru) | 2016-06-20 | 2020-07-21 | Ф-Стар Бета Лимитед | Партнеры по связыванию lag-3 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| CN111741976B (zh) | 2017-12-19 | 2024-09-17 | 英沃克斯制药有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
| EP3784699A4 (en) | 2018-04-25 | 2022-04-13 | Prometheus Biosciences, Inc. | OPTIMIZED ANTI-TL1A ANTIBODIES |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| GB201811450D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| EP3866760A4 (en) * | 2018-10-18 | 2022-07-20 | The Scripps Research Institute | SIV ENVELOPE TRIMER |
| BR112022007720A2 (pt) | 2019-10-24 | 2022-08-23 | Prometheus Biosciences Inc | Anticorpos humanizados para ligante 1a tnf-like (tl1a) e seus usos |
| AU2023324669A1 (en) * | 2022-08-15 | 2025-02-13 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
| US20250340667A1 (en) | 2022-08-26 | 2025-11-06 | Merck Patent Gmbh | Cancer Treatment comprising an anti-MSLN/CD137 antibody and a chemotherapeutic |
| CN119836302A (zh) | 2022-08-26 | 2025-04-15 | 默克专利股份公司 | 包括抗msln/cd137抗体和pd-1/pd-l1抑制剂的组合癌症治疗 |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2245404C3 (de) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben |
| JPS531908B2 (enExample) | 1973-11-12 | 1978-01-23 | ||
| JPS5746634B2 (enExample) | 1974-05-10 | 1982-10-04 | ||
| JPS5146628A (ja) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | Teikoirisupaakupuragu |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| DE69833459T2 (de) | 1997-12-01 | 2006-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antikörper, sowie fv moleküle, und immunkonjugate mit hoher bindungsaffinität für mesothelin und methoden für deren verwendung |
| DE19818214A1 (de) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Zündkerze für eine Brennkraftmaschine |
| EP1180123B1 (en) | 1999-05-27 | 2008-07-16 | Government of the United States as represented by the Secretary, Department of Health and Human Services | Immunoconjugates having high binding affinity |
| MXPA02010011A (es) | 2000-04-11 | 2003-04-25 | Genentech Inc | Anticuerpos multivalentes y usos para los mismos. |
| JP4578025B2 (ja) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | スパークプラグ |
| JP2003228556A (ja) | 2002-02-01 | 2003-08-15 | Casio Comput Co Ltd | 文書ファイル処理装置及びプログラム |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| EP1851244A4 (en) | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | ANTI-CD137 ANTIBODY AS A MEANS FOR THE TREATMENT OF CANCER, AND GLYCOSYLATION VARIANTS THEREOF |
| CA2600505C (en) | 2005-03-10 | 2016-05-03 | Morphotek, Inc. | Anti-mesothelin antibodies |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
| DK2215121T3 (en) | 2007-11-26 | 2016-05-02 | Bayer Ip Gmbh | ANTI-mesothelin ANTIBODIES AND USES THEREOF |
| EP3239178A1 (en) | 2007-12-14 | 2017-11-01 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
| RS51975B (sr) | 2008-04-11 | 2012-02-29 | Emergent Product Development Seattle Llc. | Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom |
| EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009313877A1 (en) | 2008-11-13 | 2011-06-30 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic combination therapies and uses thereof |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP2411416A1 (en) | 2009-03-24 | 2012-02-01 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Anti-mesothelin antibodies |
| AR076284A1 (es) | 2009-04-29 | 2011-06-01 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| MX343747B (es) | 2009-11-24 | 2016-11-22 | Medimmune Ltd | Agentes de union diana contra b7-h1. |
| EP2407487A1 (en) | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| DK2614082T3 (en) | 2010-09-09 | 2018-11-26 | Pfizer | 4-1BB BINDING MOLECULES |
| KR20140014116A (ko) | 2010-12-20 | 2014-02-05 | 제넨테크, 인크. | 항-메소텔린 항체 및 면역접합체 |
| EP3590965A1 (en) | 2011-03-29 | 2020-01-08 | Roche Glycart AG | Antibody fc variants |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| MX349096B (es) | 2011-11-28 | 2017-07-11 | Merck Patent Gmbh | Anticuerpos anti-pd-l1 y sus usos. |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| JP5276742B1 (ja) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | 点火プラグ |
| JP6307085B2 (ja) | 2012-09-27 | 2018-04-04 | ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ | メソテリン抗体および強力な抗腫瘍活性を惹起するための方法 |
| SMT201900242T1 (it) | 2012-12-03 | 2019-05-10 | Bristol Myers Squibb Co | Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici |
| EP3424952A1 (en) | 2013-03-15 | 2019-01-09 | Amgen, Inc | Heterodimeric bispecific antibodies |
| IL240838B (en) | 2013-03-15 | 2022-09-01 | Glaxosmithkline Ip Dev Ltd | Anti-3–lag binding proteins |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| GB201317622D0 (en) | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
| EP3102604B1 (en) | 2014-02-04 | 2020-01-15 | Pfizer Inc | Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| US20150307620A1 (en) | 2014-04-16 | 2015-10-29 | University Of Connecticut | Linked immunotherapeutic agonists that costimulate multiple pathways |
| JP5902757B2 (ja) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | スパークプラグ |
| WO2015198312A1 (en) | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
| TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
| WO2016025379A1 (en) | 2014-08-10 | 2016-02-18 | Federal-Mogul Ignition Company | Spark plug with improved seal |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| JP6681905B2 (ja) | 2014-09-13 | 2020-04-15 | ノバルティス アーゲー | Ａｌｋ阻害剤の併用療法 |
| TW201619200A (zh) | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| SI3623386T1 (sl) | 2015-01-08 | 2022-09-30 | BioNTech SE | Agonistična TNF receptor vezavna sredstva |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| CN107921104A (zh) | 2015-02-22 | 2018-04-17 | 索伦托治疗有限公司 | 结合cd137的抗体疗法 |
| WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
| BR112017020434A2 (pt) | 2015-05-04 | 2018-06-26 | Pieris Pharmaceuticals Gmbh | polipeptídeos de fusão, molécula de ácido nucleico, célula hospedeira, método para produzir um polipeptídeo de fusão, usos do polipeptídeo de fusão, métodos para ativar as vias de sinalização, para coestimular células, para induzir a proliferação de linfócitos t, para direcionar o agrupamento de cd137, para induzir uma resposta local de células t, para induzir uma resposta local de células nk e para induzir a produção de il-2 |
| US11008396B2 (en) | 2015-05-21 | 2021-05-18 | Alligator Bioscience Ab | Polypeptides |
| TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| JP6025921B1 (ja) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | スパークプラグ |
| JP7108535B2 (ja) | 2015-07-15 | 2022-07-28 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Ｌａｇ－３に特異的な新規タンパク質 |
| CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| ES2898958T3 (es) | 2015-07-30 | 2022-03-09 | Macrogenics Inc | Moléculas de unión a PD-1 y LAG-3 y métodos de uso de las mismas |
| WO2017025498A1 (en) | 2015-08-07 | 2017-02-16 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
| CN108026169B (zh) | 2015-09-22 | 2021-05-28 | 苏州丁孚靶点生物技术有限公司 | 抗人cd137的完全人抗体及其应用 |
| KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
| RU2761115C1 (ru) | 2015-10-02 | 2021-12-06 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| SG10201911035QA (en) | 2015-11-18 | 2020-01-30 | Merck Sharp & Dohme | Pd1 and/or lag3 binders |
| US20190330336A1 (en) | 2015-11-19 | 2019-10-31 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
| MX2018008308A (es) | 2016-01-11 | 2019-05-15 | Inhibrx Inc | Proteinas de fusion de union a 41bb multivalentes y multiespecificas. |
| JP6365802B2 (ja) | 2016-03-18 | 2018-08-01 | 大日本印刷株式会社 | 中間転写媒体と熱転写シートとの組合せ、及び印画物の形成方法 |
| ES2910365T3 (es) * | 2016-04-22 | 2022-05-12 | Alligator Bioscience Ab | Nuevos polipéptidos biespecíficos contra CD137 |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| AU2017271601A1 (en) | 2016-05-27 | 2018-12-13 | Abbvie Biotherapeutics Inc. | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| US20190106494A1 (en) | 2016-06-13 | 2019-04-11 | Askgene Pharma Inc. | PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis |
| CN107523546A (zh) * | 2016-06-20 | 2017-12-29 | 上海细胞治疗研究院 | 一种高效稳定表达抗体的nk细胞及其用途 |
| CN116903741A (zh) | 2016-06-20 | 2023-10-20 | 科马布有限公司 | 特异性结合于pd-l1的抗体或其抗原结合片段及其用途 |
| SI3472207T1 (sl) | 2016-06-20 | 2021-04-30 | F-Star Delta Limited | Vezavne molekule, ki vežejo PD-L1 in LAG-3 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2018142573A (ru) | 2016-06-20 | 2020-07-21 | Ф-Стар Бета Лимитед | Партнеры по связыванию lag-3 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| JP2019528251A (ja) | 2016-07-20 | 2019-10-10 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法 |
| AU2017332452B2 (en) | 2016-09-23 | 2021-01-07 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
| GB201616699D0 (en) | 2016-09-30 | 2016-11-16 | Mab Designs Ltd | Antibodies |
| GB201619648D0 (en) | 2016-11-21 | 2017-01-04 | Alligator Bioscience Ab | Novel antibodies and uses thereof |
| WO2018115859A1 (en) | 2016-12-20 | 2018-06-28 | Kymab Limited | Multispecific antibody with combination therapy for immuno-oncology |
| GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
| AU2018272311B2 (en) | 2017-05-26 | 2025-06-05 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
| CN110691795A (zh) | 2017-05-30 | 2020-01-14 | 百时美施贵宝公司 | 包含抗-lag3抗体、pd-1途径抑制剂和免疫治疗剂组合的组合物 |
| CN111406067B (zh) | 2017-08-04 | 2022-11-08 | 健玛保 | 与pd-l1和cd137结合的结合剂及其用途 |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| CN111741976B (zh) | 2017-12-19 | 2024-09-17 | 英沃克斯制药有限公司 | 包括pd-l1抗原结合位点的fc结合片段 |
| GB201811450D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| US12344672B2 (en) | 2018-07-12 | 2025-07-01 | Invox Pharma Limited | Antibody molecules that bind PD-L1 and CD137 |
| GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| MX2021000399A (es) | 2018-07-12 | 2021-05-27 | F Star Therapeutics Ltd | Moleculas de anticuerpo que se unen a cd137 y ox40. |
| CN114206939A (zh) | 2019-05-14 | 2022-03-18 | F-星治疗有限公司 | 用于lag-3/pd-l1双特异性抗体的施用的剂量方案 |
-
2018
- 2018-07-12 GB GBGB1811450.4A patent/GB201811450D0/en not_active Ceased
-
2019
- 2019-07-12 JP JP2021500386A patent/JP7360441B2/ja active Active
- 2019-07-12 KR KR1020217000265A patent/KR20210030925A/ko active Pending
- 2019-07-12 HU HUE19742323A patent/HUE072217T2/hu unknown
- 2019-07-12 TW TW108124775A patent/TWI839365B/zh active
- 2019-07-12 DK DK19742323.9T patent/DK3820894T3/da active
- 2019-07-12 AR ARP190101973A patent/AR115769A1/es unknown
- 2019-07-12 BR BR112021000396-7A patent/BR112021000396A2/pt unknown
- 2019-07-12 IL IL280007A patent/IL280007B2/en unknown
- 2019-07-12 SG SG11202011960XA patent/SG11202011960XA/en unknown
- 2019-07-12 HR HRP20250872TT patent/HRP20250872T1/hr unknown
- 2019-07-12 MX MX2021000397A patent/MX2021000397A/es unknown
- 2019-07-12 AU AU2019303081A patent/AU2019303081A1/en active Pending
- 2019-07-12 PL PL19742323.9T patent/PL3820894T3/pl unknown
- 2019-07-12 ES ES19742323T patent/ES3035107T3/es active Active
- 2019-07-12 CN CN201980046873.7A patent/CN112437776B/zh active Active
- 2019-07-12 EP EP19742323.9A patent/EP3820894B1/en active Active
- 2019-07-12 FI FIEP19742323.9T patent/FI3820894T3/fi active
- 2019-07-12 CA CA3103173A patent/CA3103173A1/en active Pending
- 2019-07-12 US US17/259,634 patent/US12319739B2/en active Active
- 2019-07-12 WO PCT/EP2019/068817 patent/WO2020011976A1/en not_active Ceased
- 2019-07-12 PT PT197423239T patent/PT3820894T/pt unknown
-
2020
- 2020-12-04 ZA ZA2020/07570A patent/ZA202007570B/en unknown
-
2023
- 2023-09-29 JP JP2023169048A patent/JP2023178323A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI839365B (zh) | 2024-04-21 |
| CA3103173A1 (en) | 2020-01-16 |
| WO2020011976A1 (en) | 2020-01-16 |
| EP3820894B1 (en) | 2025-05-07 |
| GB201811450D0 (en) | 2018-08-29 |
| ZA202007570B (en) | 2025-09-25 |
| JP7360441B2 (ja) | 2023-10-12 |
| US12319739B2 (en) | 2025-06-03 |
| CN112437776B (zh) | 2024-07-26 |
| CN112437776A (zh) | 2021-03-02 |
| AU2019303081A1 (en) | 2021-03-11 |
| AR115769A1 (es) | 2021-02-24 |
| BR112021000396A2 (pt) | 2021-04-06 |
| ES3035107T3 (en) | 2025-08-28 |
| TW202012448A (zh) | 2020-04-01 |
| PT3820894T (pt) | 2025-07-02 |
| DK3820894T3 (da) | 2025-06-30 |
| JP2023178323A (ja) | 2023-12-14 |
| IL280007A (en) | 2021-03-01 |
| HRP20250872T1 (hr) | 2025-09-26 |
| PL3820894T3 (pl) | 2025-10-06 |
| JP2021524269A (ja) | 2021-09-13 |
| SG11202011960XA (en) | 2020-12-30 |
| IL280007B1 (en) | 2025-01-01 |
| EP3820894A1 (en) | 2021-05-19 |
| FI3820894T3 (fi) | 2025-07-03 |
| US20210309753A1 (en) | 2021-10-07 |
| HUE072217T2 (hu) | 2025-11-28 |
| KR20210030925A (ko) | 2021-03-18 |
| IL280007B2 (en) | 2025-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007570B (en) | Mesothelin and cd137 binding molecules | |
| ZA202100718B (en) | Antibody molecules that bind cd137 and ox40 | |
| ZA202100717B (en) | Antibody molecules that bind pd-l1 and cd137 | |
| MX2019009967A (es) | Moleculas de union biespecificas que son capaces de unirse a cd137 y a antigenos tumorales, y usos de las mismas. | |
| ZA202100723B (en) | Fc binding fragments comprising a cd137 antigen-binding site | |
| MX2018010948A (es) | INMUNOGLOBULINAS DE ENLACE A TGFß1 Y USOS DE LAS MISMAS. | |
| CY1123884T1 (el) | Αντισωματα enanti-cd123 και συζευγματα και παραγωγα αυτων | |
| MX2021000392A (es) | Anticuerpos anti-mesotelina. | |
| PH12021550662A1 (en) | Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| EP4556020A3 (en) | Antibody molecules | |
| MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
| EA202191893A1 (ru) | Молекулы, связывающие рецептор трансферрина, их конъюгаты и их применение | |
| PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
| BR112017025080A2 (pt) | composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| TN2019000272A1 (en) | Anti-ilt4 antibodies and antigen-binding fragments. | |
| EA201070695A1 (ru) | Молекулы гуманизированных антител, специфичных к il-31 | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| EP4253959A3 (en) | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule | |
| MY192146A (en) | Binding molecules specific for asct2 and uses thereof | |
| EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
| PH12019500802A1 (en) | Antibodies that bind zika virus envelope protein and uses thereof | |
| MX2024015391A (es) | Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico | |
| MX2023013726A (es) | Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso. |